Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrolidine SCHEMBL448592 | 0.87 | HTR2A (0.56) | GAAMAPTTSHRHTR2AHTR2C | |
| SCHEMBL23909968 | 0.85 | KIF11 (0.59) | GAATSHRHTR2AHTR2CGLA | |
| SCHEMBL29938098 | 0.85 | MAPT (0.47) | GAAMAPTTSHRHTR2AHTR2C | |
| SCHEMBL5958684 | 0.85 | MAPT (0.47) | GAAMAPTTSHRHTR2AHTR2C | |
| SCHEMBL130594 | 0.84 | GAA (0.55) | GAAMAPTTSHRHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL7274023 | 0.82 | GAA (0.53) | GAAMAPTTSHRHTR2AHTR2C | |
| SCHEMBL7099157 | 0.82 | ALDH1A1 (0.45) | GAAMAPTTSHRHTR2AHTR2C | |
| SCHEMBL396413 | 0.82 | MAPT (0.52) | GAAMAPTTSHRHTR2AMAPK1 | |
| SCHEMBL10840661 | 0.82 | MAPT (0.52) | GAAMAPTTSHRHTR2AMAPK1 | |
| SCHEMBL13680229 | 0.79 | AR (0.43) | GAAMAPTTSHRHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| WO-2025231152-A1 | COMPOUNDS AND METHODS FOR RESTORING BETA-ADRENERGIC RECEPTOR FUNCTION | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-11-06 | — | — | WO | disclosed |
| US-20250206722-A1 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | THE SCRIPPS RESEARCH INSTITUTE | 2025-06-26 | — | — | US | disclosed |
| WO-2025043094-A1 | BENZOTHIA(DIA)ZEPINE COMPOUNDS FOR TREATMENT OF HBV AND HDV | ASSEMBLY BIOSCIENCES, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| CN-119403551-A | Small molecule inhibitors of TEA domain family members | 斯克里普斯研究学院 | 2025-02-07 | — | — | CN | disclosed |
| EP-4496570-A2 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | The Scripps Research Institute (US) | 2025-01-29 | — | — | EP | disclosed |
| EP-3293177-B1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GUANGDONG RAYNOVENT BIOTECH CO LTD (CN) | 2024-11-27 | — | — | EP | disclosed |
| WO-2024220626-A1 | SMALL MOLECULE MODULATORS OF OGG1 | AZKARRA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024177984-A1 | BENZOTHIA(DIA)ZEPINE COMPOUNDS FOR TREATMENT OF HBV AND HDV | ASSEMBLY BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| CN-101035780-A | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | MERCK SHARP & DOHME (GB) | 2007-09-12 | — | — | CN | disclosed |
| EP-1828186-A1 | PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060211702-A1 | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as Raf kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1685124-A1 | SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LTD. (GB) | 2006-08-02 | — | — | EP | disclosed |
| WO-2006065703-A1 | PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | HOLLINGWORTH GREGORY J (GB) | 2005-09-08 | — | — | US | disclosed |
| WO-2005047279-A1 | SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2005-05-26 | — | — | WO | disclosed |
| WO-2004043366-A2 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043366-A2 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| US-4731450-A | Process for perfluoroalkylation of aromatic derivatives | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1988-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206722-A1 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | YAP1, TEAD1, TEAD2 | GAA 4142/4885MAPT 126/4885TSHR 1798/4885 |
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | OPRL1, OPRK1, CNR1 | GAA 4852/4885MAPT 4853/4885TSHR 567/4885 |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | GAA 3313/4885MAPT 2852/4885TSHR 4265/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | GAA 3930/4885MAPT 4826/4885TSHR 142/4885 |
| US-20060211702-A1 | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as Raf kinase inhibitors | BRAF, RAF1, ARAF | GAA 2765/4885MAPT 3586/4885TSHR 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.